Redhill Biopharma Divests Talicia Business To Apotex Health Subsidiary For An Upfront Payment Of $18M Plus Up To An Additional $35M In Potential Sales-based Milestone Payments
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward
RedHill sold one of its medicine businesses to another company for $18 million right now, plus up to $35 million more if it sells really well. This shows RedHill is making room to focus on different, bigger products they think will make more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.